Clinicoimmunologic analysis of major AML immune profiles. (A) The proportion of immune cells and their single-marker immunophenotypes in AML patients (n = 69) in clusters 1 and 2 were compared (Mann-Whitney U test), P values corrected (Benjamini-Hochberg procedure), and results plotted on a volcano plot. Immunologic features with log2 fold change (FC) >0 are enriched in cluster 1 and features with log2 fold change <0 are more frequent in cluster 2. Age (Mann-Whitney U test) (B), allo-HSCT (χ² test) (C), and induction treatment frequency (Fisher’s exact test) (D) distributions of patients in clusters 1 and 2 were compared. The survival of patients in clusters 1 and 2 who were intensively treated (HD-cytarabine–based induction treatment; n = 59) were compared (Cox regression, log-rank test) using EFS (E), relapse-free survival (RFS) (F), and overall survival (OS) (G) as an end point. TCR clonality was compared between patients in cluster 1 and cluster 2 (Mann-Whitney U test) (G) and correlated with patient age (Spearman correlation) (I).